Crown Bioscience, Inc. (taicang)

Crown Bioscience Inc.

Henry Qixiang Li

Sheng Guo

Jie Cai

Binchen Mao

Yiyou Chen

Dawei Chen

Mengmeng Yang

Jie Yang

Daiwei Chen

Juan Zhang

The present disclosure provides a diagnostic method based on pairwise comparison of cancers using transcriptome expression data. In one embodiment, the method comprises the steps of: obtaining a first gene expression profile of a first cancer sample having a first cancer type; obtaining a second gene expression profile of a second cancer sample having a second cancer type, wherein the second cancer type is different from the first cancer type; comparing said first gene expression profile with said second gene expression profile; and selecting N genes that are most differentially expressed in the first and the second gene expression profiles to generate pairwise differentially expressed genes (DEGs), wherein N is an integer between 10 and 100.

Methods for histological diagnosis and treatment of diseases

A panel of gene expression markers for gastric cancer patient treated or to be treated by cetuximab is provided. Methods and compositions are also provided, e.g., kits, for evaluating gene expression levels of the markers and methods of using such gene expression levels to predict a gastric cancer patient's response to cetuximab.

System and method for determining Cetuximab sensitivity on gastric cancer

Provided in the disclosure relates to a panel of gene expression markers for cancer patient treated or to be treated by karenitecin. The disclosure provides methods and compositions, e.g., kits, for evaluating gene expression levels of the markers and methods of using such gene expression levels to predict a cancer patient's response to karenitecin. Such information can be used in determining prognosis and treatment options for cancer patients.

System and method for determining Kareniticin sensitivity on cancer

Gene expression signature predictive of cancer patient response to multi-kinase inhibitor is disclosed. Also disclosed are methods predicting the efficacy of the multi-kinase inhibitor for treating cancer in a patient. Also disclosed are methods for distinguishing responders from non-responders to a multi-kinase inhibitor in treating cancer. Also disclosed are methods for treating a cancer patient with a multi-kinase inhibitor.

Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same

The present invention relates to methods for treating gastric neoplasias, in particular treating patients who have been previously determined to have an EGFR biomarker. Gastric carcinoma (GC) is one of the most common and deadest cancers with &#x2212;1 million diagnoses and &#x2212;0.7 million deaths each year worldwide, with high incidence in Eastern Asia.

Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents

The present invention provides methods for the treatment of lung cancer patients, especially NSCLC with SCC or PLC using a drug against EGFR, such as an anti-EGFR antibody treatment, e.g., cetuximab. In addition, the present invention provides methods for identification or selection of lung cancer patients for the treatment with a drug against EGFR, such as an anti-EGFR antibody treatment, e.g., cetuximab based on histological determinations.

Growing community of inventors

Oceanside, CA, United States of America

Henry Qixiang Li